BDSX on Nasdaq
BIODESIX INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Burning Rock Biotech (China), MDxHealth SA or Personalis (United States), or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Diagnostic Tests brought in 89% of the revenue BIODESIX INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Diagnostic Tests | $64.7M | $79.2M |
| Development Services | $6.6M | $9.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development11¢$12.0M
- Selling, general and admin82¢$87.5M
- Interest7¢$7.7M
Out of $88.5M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $88.5M | $71.3M |
| Direct costs and expenses | $16.7M | $15.6M |
| Research and development | $12.0M | $9.6M |
| Sales, marketing, general and administrative | $87.5M | $80.5M |
| Impairment loss on intangible assets | $107.0K | $238.0K |
| Total operating expenses | $116.4M | $105.8M |
| Loss from operations | -$27.9M | -$34.5M |
| Interest expense | -$7.7M | -$8.3M |
| Loss on extinguishment of liabilities | -$248.0K | |
| Change in fair value of warrant liability, net | -$280.0K | |
| Other income , net | $604.0K | $73.0K |
| Total other expense | -$7.4M | -$8.4M |
| Net loss | -$35.3M | -$42.9M |
| Net loss per share, basic | -$4.67 | -$6.64 |
| Net loss per share, diluted | -$4.67 | -$6.64 |
| Weighted-average shares outstanding, basic | 7.6M shares | 6.5M shares |
| Weighted-average shares outstanding, diluted | 7.6M shares | 6.5M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-08-31 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $19.0M | $26.2M | |
| Accounts receivable, net of allowance for credit losses of $62 and $481 | $9.0M | $8.6M | |
| Other current assets | $4.5M | $4.6M | |
| Total current assets | $32.5M | $39.5M | |
| Property and equipment, net | $24.8M | $27.8M | |
| Intangible assets, net | $3.9M | $5.9M | |
| Operating lease right-of-use assets | $3.0M | $1.8M | |
| Goodwill | $15.0M | $15.0M | |
| Other long-term assets | $8.2M | $7.3M | |
| Total non-current assets | $55.0M | $57.8M | |
| Total assets | $87.5M | $97.2M | |
| Accounts payable | $3.1M | $2.2M | |
| Accrued liabilities | $11.0M | $10.1M | |
| Deferred revenue | $961.0K | $678.0K | |
| Current portion of operating lease liabilities | $1.4M | $719.0K | |
| Current portion of notes payable | $6.0K | $21.0K | |
| Other current liabilities | $992.0K | $641.0K | |
| Total current liabilities | $17.4M | $14.3M | |
| Long-term notes payable, net of current portion | $47.4M | $36.4M | |
| Long-term operating lease liabilities | $24.0M | $24.8M | |
| Other long-term liabilities | $1.0M | $815.0K | |
| Total non-current liabilities | $72.5M | $62.1M | |
| Total liabilities | $89.9M | $76.4M | |
| Common stock, $0.001 par value, 200,000,000 authorized; 8,253,053 (2025) and 7,274,578 (2024) shares issued and outstanding | $8.0K | $7.0K | |
| Additional paid-in capital | $495.3M | $483.4M | |
| Accumulated deficit | -$497.8M | -$462.5M | |
| Total stockholders' (deficit) equity | -$2.5M | $20.9M | |
| Total liabilities and stockholders' (deficit) equity | $87.5M | $97.2M | |
| Allowance for credit losses | $62.0K | $481.0K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, authorized | 5.0M shares | 5.0M shares | 5.0M shares |
| Preferred stock, issued | 0 shares | 0 shares | |
| Preferred stock, outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, authorized | 200.0M shares | 200.0M shares | 200.0M shares |
| Common stock, issued | 8.3M shares | 7.3M shares | |
| Common stock, outstanding | 8.3M shares | 7.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$35.3M | -$42.9M |
| Depreciation and amortization | $5.7M | $5.8M |
| Accretion of lease right-of-use assets | -$69.0K | -$317.0K |
| Loss on extinguishment of liabilities | $248.0K | |
| Share-based compensation expense | $4.1M | $6.6M |
| Change in fair value of warrant liability, net | $280.0K | |
| Provision for credit losses | $180.0K | $887.0K |
| Accrued interest, amortization of debt issuance costs and other | $1.3M | $2.5M |
| Inventory excess and obsolescence | $49.0K | $22.0K |
| Impairment loss on intangible assets | $107.0K | $238.0K |
| Accounts receivable | -$531.0K | -$1.8M |
| Other current assets | -$258.0K | $716.0K |
| Other long-term assets | -$121.0K | $68.0K |
| Accounts payable and other accrued liabilities | $1.9M | $1.6M |
| Deferred revenue | $174.0K | $248.0K |
| Contingent consideration | -$23.2M | |
| Current and long-term operating lease liabilities | -$789.0K | $715.0K |
| Net cash, cash equivalents, and restricted cash used in operating activities | -$23.3M | -$48.6M |
| Purchase of property and equipment | -$259.0K | -$3.2M |
| Patent costs and intangible asset acquisition, net | -$144.0K | -$210.0K |
| Net cash, cash equivalents, and restricted cash used in investing activities | -$403.0K | -$3.4M |
| Proceeds from the issuance of common stock | $7.3M | $55.6M |
| Proceeds from issuance of common stock under employee stock purchase plan | $497.0K | $625.0K |
| Proceeds from exercise of stock options | $25.0K | |
| Proceeds from term loan and notes payable | $10.0M | |
| Repayment of term loan and notes payable | -$21.0K | -$51.0K |
| Payment of debt issuance costs | -$30.0K | -$44.0K |
| Equity financing costs | -$532.0K | -$3.7M |
| Other | -$817.0K | -$445.0K |
| Net cash, cash equivalents, and restricted cash provided by financing activities | $16.4M | $52.0M |
| Net decrease in cash, cash equivalents, and restricted cash | -$7.3M | -$39.0K |
| Equity financing costs included in accounts payable and other accrued liabilities | $7.0K | |
| Operating lease right-of-use asset obtained in exchange for lease liabilities | $644.0K | $583.0K |
| Finance lease right-of-use assets obtained in exchange for lease liabilities | $1.4M | $999.0K |
| Cash paid for interest | $6.4M | $7.0M |
| Change in fair value of Perceptive Warrants | $227.0K | |
| Reclassification of Tranche C warrants to additional paid-in capital | $280.0K | |
| Purchases of property & equipment included in accounts payable and accrued liabilities | $27.0K |
Recent filings
- Oct 2, 20264
- Aug 13, 20264
- Aug 12, 20264
- Aug 5, 20268-K
- Aug 5, 202610-Q
- Jul 2, 20264
- Jun 18, 2026SCHEDULE 13G
- Jun 1, 2026424B3
- May 29, 2026EFFECT
- May 27, 2026CORRESP
- May 26, 2026UPLOAD
- May 21, 2026S-3
- May 20, 20268-K
- May 15, 2026SCHEDULE 13G/A
- May 8, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIODESIX INC filings on SEC EDGAR
- 2SEC EDGARBIODESIX INC filings on SEC EDGAR
- 3SEC EDGARBIODESIX INC 10-K for fiscal 2025
- 4SEC EDGARBIODESIX INC 10-K for fiscal 2019
- 5SEC EDGARBIODESIX INC 10-K for fiscal 2020
- 6SEC EDGARBIODESIX INC 10-K for fiscal 2021
- 7SEC EDGARBIODESIX INC 10-K for fiscal 2022
- 8SEC EDGARBIODESIX INC 10-K for fiscal 2023
- 9SEC EDGARBIODESIX INC 10-Q for fiscal 2026
- 10SEC EDGARBIODESIX INC 10-Q for fiscal 2026